However, in MASLD patients, the onset of insulin resistance diminishes the liver’s ability to respond to insulin, resulting in enhanced gluconeogenesis and elevated blood glucose levels (36). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.